Shattuck falls as quarterly net loss widens

Shattuck Labs

11/08/2026 11:50

** Shares of drug developer Shattuck Labs STTK.O fall 1.8% to $7.01 premarket
** Co reports Q2 net loss of $15.2 million compared to a net loss of $12.5 million a year ago
** STTK's Q2 R&D expenses rose 34% to $11.7 million
** Analysts, on average, expected R&D expense of $10.9 million, according to LSEG data
** Co has $208.3 million in cash and its equivalents and investments as of June 30 which are expected to fund operations into 2029
** Co is specializing in the development of potential treatments for inflammatory and immune-mediated diseases
** Up to last close, stock up 95.6% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))